Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Norway / NCT06270667
Recruiting Not applicable

Effects of Exercise Training in Survivors of Lymphoma

NCT06270667 · tracked via the Priya Life Science Norway tracker
Phase
Not applicable
Started
2024-03-20
Last updated
2024-03-22

Condition(s) studied

LymphomaPhysical ExerciseCardiotoxicityCardiovascular DiseasesChemotherapeutic Toxicity

Investigational drug(s) / intervention(s)

Aerobic ExerciseCombined Aerobic and Resistance Exercise

Aerobic Exercise: Participants receive twice weekly supervised aerobic treadmill-based exercise sessions for five months. Session duration varies from 20 to 60 minutes, including warm-up, with exercise intensity ranging from 60 to 95% of peak heart rate. Maximal exercise capacity (VO2peak and peak heart rate) will be determined by the CPET performed by certified exercise physiologists at baseline.The exercise prescription will be sequenced so that the exercise intensity and -duration of each exercise varies within each week, leading to an accumulative increase in weekly exercise volume throughout the intervention. This intervention is also given to the Active Comparator group (i.e. non-cancer reference group)

Combined Aerobic and Resistance Exercise: Twice weekly, supervised combined aerobic and resistance exercise sessions will be offered to participants. Participants randomized to the combined aerobic and resistance training group will follow the same aerobic exercise prescription as described for the Aerobic Exercise arm. In addition, participants in this group will perform five resistance exercises after the aerobic sessions. The resistance exercises will be leg press, knee extension, and calf rise, followed by seated row and chest press. Following familiarization, the training load will progressively increase following a linear periodization model throughout the intervention. exercise prescription will be sequenced so that the exercise intensity and -duration of each exercise varies within each week, leading to an accumulative increase in weekly exercise volume throughout the intervention. Only Lymphoma participants can be randomized to this arm.

Study summary

This study aims to compare the effects of aerobic exercise with or without addition of resistance exercise to usual care in individuals treated with anthracyclines for lymphomas and to compare exercise effects to age- and sex-matched individuals with no prior history of malignant diseases.

Eligibility

Sex
ALL
Min age
20 Years
Max age
70 Years
Healthy volunteers
Accepted
Inclusion Criteria Lymphoma participants: * Listed in relevant registers * Confirmed lymphoma diagnosis (i.e., Hodgkin lymphoma and aggressive non-Hodgkin lymphoma) * Completed treatment in the past two to five years without relapse or second cancer * Previous anthracycline treatment with or without mediastinal radiation * No severe cancer-related fatigue (per self-report) Inclusion Criteria Lymphoma participants and non-cancer reference group: * Currently not performing \>75 minutes/week of aerobic exercise * Willing and able to adhere to all study procedures. Exclusion Criteria Lymphoma participants: * Relapse since diagnosis * A history, or current presence, of another diagnosis of invasive cancer of any kind Exclusion Criteria Lymphoma participants and non-cancer reference group: * Presence of any uncontrolled- or recent cardiovascular disease * Has undergone heart surgery * Uses a pacemaker * Pregnancy * Unable to read and understand Swedish (applicable for the Swedish site only) * Unable to read and understand Norwegian (applicable for the Norwegian site) * Any physical or mental health condition restricting adherence to study protocol

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Norweigan School of Sport Sciences Oslo Norway Not Yet Recruiting
Helena Igelström Uppsala Sweden Recruiting

More Norwegian School of Sport Sciences trials in Norway

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06270667 on ClinicalTrials.gov ↗ ← All trials in Norway